Compare ITP & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITP | XBIO |
|---|---|---|
| Founded | 1996 | N/A |
| Country | China | United States |
| Employees | N/A | 2 |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 5.2M |
| IPO Year | 2020 | N/A |
| Metric | ITP | XBIO |
|---|---|---|
| Price | $0.19 | $2.81 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 150.0K | 23.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $75,837,943.00 | N/A |
| Revenue This Year | N/A | $1.99 |
| Revenue Next Year | N/A | $20.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.16 | $1.90 |
| 52 Week High | $1.00 | $13.93 |
| Indicator | ITP | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 38.03 | 63.54 |
| Support Level | $0.16 | $2.59 |
| Resistance Level | $0.22 | $3.21 |
| Average True Range (ATR) | 0.01 | 0.18 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 46.38 | 79.64 |
IT Tech Packaging Inc is a holding company engaged in the business of paper manufacturing in China. The company operates as a producer and distributor of paper products. It is involved in the production and distribution of three categories of paper products: packing paper (corrugating medium paper), offset printing paper, and tissue paper products. It also produces digital photo paper. Its business is structured into three segments: Dongfang Paper and Tengsheng Paper, which produce offset printing paper, corrugating medium paper, and tissue paper, and Baoding Shengde, which produces face masks and digital photo paper.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.